Interaksi Digoksin

Digoksin (Lanoxin, Digitek), golongan glikosida digitalis, memiliki 373 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 31 mayor, 281 moderat, 42 minor, dan 19 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (31)

  • AmiodaronantiaritmiaMayor

    Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (label Amiodaron, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopMayor

    These generally have fallen into two categories: (1) patients with severe myocardial disease who have been receiving digitalis and presumably developed acute hypokalemia with fatal arrhythmia; (2) patients with severely decompensated hepatic cirrhosis with ascites, with or without accompanying encephalopathy, who were in electrolyte imbalance and died because… (label Asam etakrinat, Peringatan)

  • AsenapinantipsikotikMayor

    The use of SAPHRIS should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). (label Asenapin, Peringatan dan perhatian)

  • AtazanavirantiretroviralMayor

    Drug Class Drugs within class that are contraindicated with REYATAZ Alpha 1-adrenoreceptor antagonist Alfuzosin Anticonvulsants Carbamazepine, phenobarbital, phenytoin Antiarrhythmics Amiodarone (with ritonavir), quinidine (with ritonavir) Antimycobacterials Rifampin Antineoplastics Apalutamide, encorafenib, irinotecan, ivosidenib Antipsychotics Lurasidone (with… (label Atazanavir, Kontraindikasi)

  • DisopiramidantiaritmiaMayor

    Considering the known proarrhythmic properties of Norpace or Norpace CR and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of Norpace or Norpace CR as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias. (label Disopiramid, Peringatan kotak hitam)

  • DofetilidantiaritmiaMayor

    NA – Not available/reported 7.3 Pharmacodynamic Drug Interactions Antiarrhythmics Dofetilide Concomitant administration with digoxin was associated with a higher rate of torsades de pointes . (label Digoksin, Interaksi obat)

  • DronedaronantiaritmiaMayor

    Digoxin In the ANDROMEDA (patients with recently decompensated heart failure) and PALLAS (patients with permanent AF) trials baseline use of digoxin was associated with an increased risk of arrhythmic or sudden death in dronedarone-treated patients compared to placebo. (label Dronedaron, Interaksi obat)

  • Feri sitratpengikat fosfatMayor

    Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (label Feri sitrat, Interaksi obat)

  • FlekainidantiaritmiaMayor

    Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (label Flekainid, Peringatan kotak hitam)

  • FosamprenavirantiretroviralMayor

    Fosamprenavir calcium is contraindicated when coadministered with the following drugs: Alpha 1-adrenoreceptor antagonist: Alfuzosin Antiarrhythmics: Flecainide (with ritonavir ), propafenone (with ritonavir ) Antimycobacterial: Rifampin Antipsychotic: Lurasidone (with ritonavir ), pimozide Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine… (label Fosamprenavir, Kontraindikasi)

  • FosfomisinantibiotikMayor

    Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (label Fosfomisin, Interaksi obat)

  • Itrakonazolantijamur azolMayor

    Antiarrhythmics Disopyramide Dofetilide Dronedarone Quinidine Contraindicated during and 2 weeks after TOLSURA treatment. (label Itrakonazol, Interaksi obat)

  • Administration of Calcium Gluconate Injection should be avoided in patients receiving cardiac glycosides. (label Kalsium glukonat, Peringatan dan perhatian)

  • • Arrhythmias with Concomitant Digoxin Use: Avoid use of Calcium Chloride Injection in patients receiving digoxin. (label Kalsium klorida, Peringatan dan perhatian)

  • Klaritromisinantibiotik makrolidaMayor

    Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. (label Klaritromisin, Interaksi obat)

  • KuinidinantiaritmiaMayor

    Proarrhythmic effects Like many other drugs (including all other Class Ia antiarrhythmics), quinidine prolongs the QT c interval, and this can lead to torsades de pointes , a life-threatening ventricular arrhythmia (see OVERDOSAGE ). (label Kuinidin, Peringatan)

  • Lapatinibpenghambat P-glikoproteinMayor

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (label Lapatinib, Peringatan dan perhatian)

  • Coadministration of amiodarone with ledipasvir and sofosbuvir is not recommended; if coadministration is required, cardiac monitoring is recommended [see Warnings and Precautions (5.2) , Adverse Reactions (6.2) ]. digoxin ↑ digoxin Coadministration of ledipasvir and sofosbuvir with digoxin may increase the concentration of digoxin. (label Ledipasvir dan sofosbuvir, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin… (label Lopinavir dan ritonavir, Kontraindikasi)

  • MeksiletinantiaritmiaMayor

    Considering the known proarrhythmic properties of mexiletine and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of mexiletine as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmia. (label Meksiletin, Peringatan kotak hitam)

  • MilnasipranSNRIMayor

    Avoid co-administration of milnacipran hydrochloride and intravenous digoxin [see Warnings and Precautions ( 5.3 , 5.4 )] . (label Milnasipran, Interaksi obat)

  • MoksifloksasinfluorokuinolonMayor

    Therefore, moxifloxacin should be avoided with Class IA and Class III antiarrhythmics [see Warnings and Precautions ( 5.6 ), Nonclinical Toxicology ( 13.2 ), and Patient Counseling Information ( 17 )]. (label Moksifloksasin, Interaksi obat)

  • Nifedipinpenghambat kanal kalsium dihidropiridinMayor

    Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine extended-release tablet, it is recommended that digoxin levels be monitored when initiating, adjusting and discontinuing nifedipine extended-release tablet to avoid possible over- or under-digitalization. (label Nifedipin, Interaksi obat)

  • …concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7.3) ] : • Alpha 1-adrenoreceptor antagonist: alfuzosin • Antianginal: ranolazine • Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine • Anti-gout: colchicine (in patients with renal and/or hepatic impairment [see Table 2 , Drug Interactions… (label Nirmatrelvir dan ritonavir, Kontraindikasi)

  • ProkainamidantiaritmiaMayor

    Considering the known proarrhythmic properties of procainamide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of procainamide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias. (label Prokainamid, Peringatan kotak hitam)

  • PropafenonantiaritmiaMayor

    • The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any IC antiarrhythmic to have a significant proarrhythmic risk in patients with structural heart disease. (label Propafenon, Peringatan kotak hitam)

  • RitonavirantiretroviralMayor

    WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (label Ritonavir, Peringatan kotak hitam)

  • Coadministration of amiodarone with VOSEVI is not recommended; if coadministration is required, cardiac monitoring is recommended [see Warnings and Precautions (5.3) ]. digoxin ↑ digoxin Therapeutic concentration monitoring of digoxin is recommended when coadministered with VOSEVI. (label Sofosbuvir dan velpatasvir, Interaksi obat)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronMayor

    Thiazide-induced electrolyte disturbances, i.e. hypokalemia, hypomagnesemia, increase the risk of digoxin toxicity, which may lead to fatal arrhythmic events (see Precautions ). (label Spironolakton dan hidroklorotiazid, Interaksi obat)

  • St. John's wortHerbal dan suplemenMayor

    St. John's wort dapat melemahkan obat-obat ini dengan mempercepat penguraiannya, yang dapat berarti penolakan organ, bekuan darah, atau hilangnya efek. (NCCIH, St. John's Wort)

  • Vardenafilpenghambat PDE5Mayor

    QT Prolongation : Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil hydrochloride tablets. (label Vardenafil, Peringatan dan perhatian)

Interaksi moderat (281)

  • AkarbosaantidiabetesModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • AlprazolambenzodiazepinModerat

    …Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations… (label Digoksin, Interaksi obat)

  • Amfetaminstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Amfoterisin BantijamurModerat

    Digitalis Glycosides Concurrent use may induce hypokalemia and may potentiate digitalis toxicity. (label Amfoterisin B, Interaksi obat)

  • Amiloriddiuretik hemat kaliumModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Amlodipinpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Antasida (Tums, Maalox, Mylanta)Produk obat bebasModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Arformoterolagonis beta-adrenergikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Armodafinilstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Artikain dan epinefrinanestetik lokalModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Asam mefenamatOAINSModerat

    Digoxin Clinical Impact: The concomitant use of mefenamic acid with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (label Asam mefenamat, Interaksi obat)

  • Asam zoledronatbisfosfonatModerat

    In patients with renal impairment, the exposure to concomitant medications that are primarily renally excreted (e.g., digoxin) may increase. (label Asam zoledronat, Interaksi obat)

  • Asebutololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Asetazolamidpenghambat karbonat anhidraseModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Atenololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Atenolol dan klortalidonpenyekat betaModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • AtorvastatinstatinModerat

    • Digoxin: May increase digoxin plasma levels; monitor patients appropriately ( 7.3 ). (label Atorvastatin, Interaksi obat)

  • Azelastin dan flutikasonantihistaminModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Azitromisinantibiotik makrolidaModerat

    …Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations… (label Digoksin, Interaksi obat)

  • BeklometasonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Benazepril dan hidroklorotiazidpenghambat ACEModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Benzfetaminstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Betaksololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • BetametasonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Table 4 Drug Interactions with BIXLENVO Concomitant Drug Class: Drug Name Effect on Concentration ↑ = Increase, ↓ = Decrease Clinical Comment Antiarrhythmics: digoxin dofetilide ↑ digoxin ↑ dofetilide Use digoxin with caution and monitor digoxin therapeutic concentration. (label Biktegravir, emtrisitabin, dan tenofovir alafenamid, Interaksi obat)

  • Bisoprololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Brimonidinagonis alfa-adrenergikModerat

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (label Brimonidin, Interaksi obat)

  • Brimonidin dan timololagonis alfa-adrenergikModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • BudesonidkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Bumetaniddiuretik loopModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Bupivakain dan epinefrinanestetik lokalModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • BuprenorfinopioidModerat

    …in clinical decisions when prescribing BELBUCA to patients with risk factors such as hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia [see Dosage and Administration (2.4) , Adverse Reactions (6.1) , Clinical Pharmacology… (label Buprenorfin, Peringatan dan perhatian)

  • Consider these observations in clinical decisions when prescribing buprenorphine and naloxone sublingual tablets to patients with risk factors such as hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia. (label Buprenorfin dan nalokson, Peringatan dan perhatian)

  • BupropionantidepresanModerat

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (label Bupropion, Interaksi obat)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Dapagliflozinpenghambat SGLT2Moderat

    …mg ↔ ↔ Bumetanide (1 mg) 10 mg once daily for 7 days ↑13% [↓2%, ↑31%] ↑13% [↓1%, ↑30%] Valsartan (320 mg) 20 mg ↓6% [↓24%, ↑16%] ↑5% [↓15%, ↑29%] Simvastatin (40 mg) 20 mg ↔ ↑19% Digoxin (0.25 mg) 20 mg loading dose then 10 mg once daily for 7 days ↔ ↔ Warfarin (25 mg) 20 mg loading dose then 10 mg once daily for 7 days ↔ ↔ ↔ = no change (geometric mean ratio… (label Dapagliflozin, Interaksi obat)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • DarifenasinantikolinergikModerat

    Routine therapeutic drug monitoring for digoxin should be continued [see Clinical Pharmacology (12.3)] . (label Darifenasin, Interaksi obat)

  • DarunavirantiretroviralModerat

    The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect. (label Darunavir, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralModerat

    Other antiarrhythmics e.g. amiodarone, disopyramide, flecainide, lidocaine (systemic), mexiletine, propafenone, quinidine ↑ antiarrhythmics Clinical monitoring is recommended upon co-administration with antiarrhythmics. digoxin ↑ digoxin When co-administering with digoxin, titrate the digoxin dose and monitor digoxin concentrations. (label Darunavir dan kobisistat, Interaksi obat)

  • DasatinibModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • DeflazakortkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • DeksametasonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Dekslansoprazolpenghambat pompa protonModerat

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (label Dekslansoprazol, Peringatan dan perhatian)

  • Deksmetilfenidatstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Dekstroamfetaminstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Dekstrometorfan dan kuinidinobat serotonergikModerat

    Digoxin: Increased digoxin substrate plasma concentration may occur. (label Dekstrometorfan dan kuinidin, Interaksi obat)

  • DesonidkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Dietilpropionstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • DiklofenakOAINSModerat

    …Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant… (label Digoksin, Interaksi obat)

  • …Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant… (label Digoksin, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumModerat

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (label Digoksin, Interaksi obat)

  • DisikloverinantikolinergikModerat

    Effect on Absorption of Other Drugs Anticholinergic agents may affect gastrointestinal absorption of various drugs by affecting on gastrointestinal motility, such as slowly dissolving dosage forms of digoxin; increased serum digoxin concentration may result. (label Disikloverin, Interaksi obat)

  • DobutaminsimpatomimetikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Dokserkalsiferolanalog vitamin DModerat

    Digitalis Toxicity: Hypercalcemia increases the risk of digitalis toxicity. (label Dokserkalsiferol, Peringatan dan perhatian)

  • Dorzolamid dan timololpenghambat karbonat anhidraseModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • DroksidopasimpatomimetikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Droperidolantagonis dopaminModerat

    …development of prolonged QT syndrome, such as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS,… (label Droperidol, Peringatan)

  • Dutasteridpenghambat 5-alfa reduktaseModerat

    Digoxin Dutasteride capsules do not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks [see Clinical Pharmacology (12.3) ]. (label Dutasterid, Interaksi obat)

  • Dutasterid dan tamsulosinpenghambat 5-alfa reduktaseModerat

    Tamsulosin Dosage adjustments are not necessary when tamsulosin is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology (12.3) ]. (label Dutasterid dan tamsulosin, Interaksi obat)

  • EfedrinsimpatomimetikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Eksenatidagonis reseptor GLP-1Moderat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Transporters Concomitant use of ivacaftor or tezacaftor/ivacaftor with digoxin, a sensitive P-gp substrate, increased digoxin AUC by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. (label Eleksakaftor, tezakaftor, dan ivakaftor, Interaksi obat)

  • Antiarrhythmics: e.g., amiodarone bepridil digoxin Indicates that a drug-drug interaction trial was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine ↑ antiarrhythmics ↑ digoxin Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when coadministered with GENVOYA. (label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir, Interaksi obat)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • EpinefrinsimpatomimetikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Eplerenonantagonis aldosteronModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Epoprostenolanalog prostaglandinModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • Ergotamin dan kafeinalkaloid ergotModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • EribulinModerat

    ECG monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities. (label Eribulin, Peringatan dan perhatian)

  • Eritromisinantibiotik makrolidaModerat

    Erythromycin should be avoided in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (label Eritromisin, Peringatan)

  • Esmololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Esomeprazolpenghambat pompa protonModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • EtodolakOAINSModerat

    Cyclosporine, Digoxin, Methotrexate Etodolac, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity. (label Etodolak, Interaksi obat)

  • EtravirinantiretroviralModerat

    Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (label Etravirin, Interaksi obat)

  • Digoxin : During VYTORIN initiation, monitor digoxin levels. (label Ezetimib dan simvastatin, Interaksi obat)

  • FamsiklovirantivirusModerat

    Potential for Famciclovir to Affect Other Drugs The steady-state pharmacokinetics of digoxin were not altered by concomitant administration of multiple doses of famciclovir (500 mg three times daily). (label Famsiklovir, Interaksi obat)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Fendimetrazinstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • FenilefrindekongestanModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • FenitoinantikonvulsanModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • FenoprofenOAINSModerat

    Digoxin Clinical Impact: The concomitant use of fenoprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (label Fenoprofen, Interaksi obat)

  • FentanilopioidModerat

    …as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, including baseline prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte… (label Fentanil, Peringatan dan perhatian)

  • Fenterminstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Flibanserindepresan SSPModerat

    Digoxin or Other P-glycoprotein Substrates Examples Digoxin, sirolimus Clinical Implications The concomitant use of ADDYI with digoxin, a drug that is transported by P-glycoprotein (P-gp), increases the digoxin concentration [see Clinical Pharmacology (12.3) ] . (label Flibanserin, Interaksi obat)

  • FludrokortisonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • FlunisolidkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • FluoksetinSSRIModerat

    Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. (label Fluoksetin, Interaksi obat)

  • FluosinonidkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • FlurbiprofenOAINSModerat

    Digoxin Clinical Impact: The concomitant use of flurbiprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin [ see Clinical Pharmacology (12.3) ]. (label Flurbiprofen, Interaksi obat)

  • FlutikasonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Formoterolagonis beta-adrenergikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • FosfenitoinantikonvulsanModerat

    …concentration of amprenavir Calcium channel blockers Nifedipine, nimodipine, nisoldipine, verapamil Other Albendazole (decreases active metabolite), chlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine 7.3 Hyperammonemia with Concomitant Use of Valproate Concomitant administration of phenytoin and valproate… (label Fosfenitoin, Interaksi obat)

  • Fosinoprilpenghambat ACEModerat

    In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propranolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs. (label Fosinopril, Interaksi obat)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • FoskarnetantivirusModerat

    …prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic antidepressants, and certain macrolides and fluoroquinolones. (label Foskarnet, Interaksi obat)

  • Furosemiddiuretik loopModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Glibenklamid dan metforminsulfonilureaModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • GlikopironiumantikolinergikModerat

    Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (label Glikopironium, Interaksi obat)

  • Glipizid dan metforminsulfonilureaModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • HalobetasolkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Hidroklorotiaziddiuretik tiazidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • HidrokortisonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Hidroksiklorokuinobat yang memperpanjang interval QTModerat

    Digoxin Concomitant PLAQUENIL and digoxin therapy may result in increased serum digoxin levels. (label Hidroksiklorokuin, Interaksi obat)

  • IbuprofenOAINSModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • IbutilidantiaritmiaModerat

    Digoxin: Supraventricular arrhythmias may mask the cardiotoxicity associated with excessive digoxin levels. (label Ibutilid, Interaksi obat)

  • IloperidonantipsikotikModerat

    …FANAPT should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to… (label Iloperidon, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • IndometasinOAINSModerat

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (label Digoksin, Interaksi obat)

  • Ipratropium dan salbutamolantikolinergikModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Isoprenalinagonis beta-adrenergikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • IvabradinModerat

    Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel Blocker Ivabradine can increase the risk of bradycardia. (label Digoksin, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Moderat

    Co-administration with digoxin, a sensitive P-gp substrate, increased digoxin exposure by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. (label Ivakaftor, Interaksi obat)

  • Kalsitriolanalog vitamin DModerat

    Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias (see PRECAUTIONS: General ). (label Kalsitriol, Interaksi obat)

  • Kalsium asetatpengikat fosfatModerat

    Hypercalcemia may aggravate digitalis toxicity. (label Kalsium asetat, Peringatan dan perhatian)

  • Kanabidiol (obat resep)antikonvulsanModerat

    Increases in exposure of other orally administered P‑gp substrates (e.g., sirolimus, tacrolimus, digoxin) may be observed when concomitantly used with EPIDIOLEX. (label Kanabidiol (obat resep), Interaksi obat)

  • Kanagliflozinpenghambat SGLT2Moderat

    Digoxin Clinical Impact: Canagliflozin increases digoxin exposure [see Clinical Pharmacology (12.3) ] . (label Kanagliflozin, Interaksi obat)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (label Digoksin, Interaksi obat)

  • Ketokonazolantijamur azolModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • KetorolakOAINSModerat

    Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL. (label Ketorolak, Interaksi obat)

  • KlobetasolkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Klomipraminantidepresan trisiklikModerat

    Because clomipramine hydrochloride capsules are highly bound to serum protein, the administration of clomipramine hydrochloride capsules to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects. (label Klomipramin, Interaksi obat)

  • Klonidinagonis alfa-adrenergikModerat

    Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers) Clinical Implication Concomitant use of drugs that affect sinus node function or AV node conduction with clonidine potentiate bradycardia and risk of AV block [see Warnings and Precautions (5.1) ]. (label Klonidin, Interaksi obat)

  • Klorotiaziddiuretik tiazidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • KlozapinantipsikotikModerat

    …droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). (label Klozapin, Peringatan dan perhatian)

  • Kolestipolsekuestran asam empeduModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Kolestiraminsekuestran asam empeduModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • KuininantimalariaModerat

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (label Digoksin, Interaksi obat)

  • Labetalolpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Lansoprazolpenghambat pompa protonModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • LenakapavirantiretroviralModerat

    Clinical Comment Antiarrhythmics: digoxin ↑ digoxin Use with caution and monitor digoxin therapeutic concentration. (label Lenakapavir, Interaksi obat)

  • • Digoxin: Monitor digoxin plasma levels periodically due to increased C max and AUC with concomitant REVLIMID therapy ( 7.1 ). (label Lenalidomid, Interaksi obat)

  • LevetirasetamantikonvulsanModerat

    Digoxin Levetiracetam (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day. (label Levetirasetam, Interaksi obat)

  • LevofloksasinfluorokuinolonModerat

    Levofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. (label Levofloksasin, Peringatan dan perhatian)

  • Levosalbutamolagonis beta-adrenergikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Levotiroksinhormon tiroidModerat

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (label Digoksin, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidModerat

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (label Digoksin, Peringatan dan perhatian)

  • Lidokain dan epinefrinanestetik lokalModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • Liotironinhormon tiroidModerat

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (label Digoksin, Peringatan dan perhatian)

  • Lisdeksamfetaminstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • LomitapidModerat

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (label Lomitapid, Interaksi obat)

  • Loperamidobat yang memperpanjang interval QTModerat

    …combination with others drugs or herbal products that are known to prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), or any other drug known to prolong the QT interval… (label Loperamid, Peringatan)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • MetadonopioidModerat

    Examples: Drugs known to have potential to prolong QT interval: Class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers. (label Metadon, Interaksi obat)

  • Metamfetaminstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • MetforminbiguanidModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • Metilfenidatstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • MetilprednisolonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Metoklopramidantagonis dopaminModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Metolazondiuretik tiazidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Metoprololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Midodrinagonis alfa-adrenergikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • MiglitolantidiabetesModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Mirabegronagonis beta-adrenergikModerat

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (label Digoksin, Interaksi obat)

  • Modafinilstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • MometasonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Nadololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Naltrekson dan bupropionantagonis opioidModerat

    Digoxin: May decrease plasma digoxin levels. (label Naltrekson dan bupropion, Interaksi obat)

  • NaproksenOAINSModerat

    Digoxin Clinical Impact: The concomitant use of naproxen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin Intervention: During concomitant use of Naproxen Suspension and digoxin, monitor serum digoxin levels. (label Naproksen, Interaksi obat)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • Natrium bikarbonatantasidaModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Nebivololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • NefazodonantidepresanModerat

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (label Digoksin, Interaksi obat)

  • NeomisinaminoglikosidaModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • NevirapinantiretroviralModerat

    Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (label Nevirapin, Interaksi obat)

  • Nikardipinpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Nimodipinpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • OfloksasinfluorokuinolonModerat

    Ofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. (label Ofloksasin, Perhatian)

  • Monitor electrocardiograms (ECG) in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities and in patients taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics [see Drug Interactions (7.1)] . (label Oksaliplatin, Peringatan dan perhatian)

  • OksaprozinOAINSModerat

    Digoxin Clinical Impact: The concomitant use of oxaprozin with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (label Oksaprozin, Interaksi obat)

  • OksimetazolindekongestanModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • OktreotidModerat

    Digoxin: exposure may be decreased and assessment of clinical response to digoxin should be performed (‎ 7 ). (label Oktreotid, Interaksi obat)

  • Olanzapin dan fluoksetinantipsikotikModerat

    Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. (label Olanzapin dan fluoksetin, Interaksi obat)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Omeprazolpenghambat pompa protonModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • PaliperidonantipsikotikModerat

    …paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to… (label Paliperidon, Peringatan dan perhatian)

  • Pantoprazolpenghambat pompa protonModerat

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (label Pantoprazol, Peringatan dan perhatian)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • Parikalsitolanalog vitamin DModerat

    Digitalis Toxicity: Risk increases with hypercalcemia. (label Parikalsitol, Peringatan dan perhatian)

  • PazopanibModerat

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (label Pazopanib, Peringatan dan perhatian)

  • Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • PimavanserinantipsikotikModerat

    The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain… (label Pimavanserin, Peringatan dan perhatian)

  • PimozidantipsikotikModerat

    DRUG INTERACTIONS Because pimozide prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with other drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval. (label Pimozid, Interaksi obat)

  • Pindololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Pioglitazon dan metformintiazolidindionModerat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • PiroksikamOAINSModerat

    Digoxin: Concomitant use of Piroxicam Capsules can increase serum concentration and prolong half-life of digoxin. (label Piroksikam, Interaksi obat)

  • PonesimodimunosupresanModerat

    Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (label Ponesimod, Peringatan dan perhatian)

  • Posakonazolantijamur azolModerat

    Digoxin Monitor digoxin plasma concentrations ( 7.2 ) (label Posakonazol, Interaksi obat)

  • PrednisolonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • PrednisonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Prilokain dan epinefrinanestetik lokalModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • PrimakuinantimalariaModerat

    P-gp Substrates Refer to the Prescribing Information for a P-gp substrate where minimal concentration changes may lead to serious adverse reactions (e.g., digoxin and dabigatran) for the recommended dosage modification and/or monitoring. (label Primakuin, Interaksi obat)

  • Propiltiourasilobat antitiroidModerat

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (label Digoksin, Peringatan dan perhatian)

  • Propranololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • PseudoefedrindekongestanModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Rabeprazolpenghambat pompa protonModerat

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (label Digoksin, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTModerat

    Drugs transported by P-gp (e.g., digoxin), or drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants) may need reduced doses when used with ASPRUZYO Sprinkle. (label Ranolazin, Interaksi obat)

  • RifampisinantibiotikModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • RifapentinantibiotikModerat

    …itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins… (label Rifapentin, Interaksi obat)

  • Rolapitantpenghambat CYP2D6Moderat

    P-gp Substrates with a Narrow Therapeutic Index (e.g. digoxin) Clinical Impact: Increased plasma concentrations of P-gp substrates (e.g., digoxin) may result in potential adverse reactions [see Clinical Pharmacology (12.3) ]. (label Rolapitant, Interaksi obat)

  • Ropivakainanestetik lokalModerat

    …anesthetics or agents structurally related to amide- type local anesthetics, since the toxic effects of these drugs are additive. [See Drug Interactions 7.0 ] Patients treated with class III antiarrhythmic drugs (e.g., amiodarone) should be under close surveillance and ECG monitoring considered, since cardiac effects may be additive. [See Drug Interactions 7.0… (label Ropivakain, Peringatan dan perhatian)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • Salbutamolagonis beta-adrenergikModerat

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

  • Salmeterolagonis beta-adrenergikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • SelekoksibOAINSModerat

    Digoxin Clinical Impact: The concomitant use of Celecoxib with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (label Selekoksib, Interaksi obat)

  • SiklesonidkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • SiklosporinimunosupresanModerat

    …25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating… (label Digoksin, Interaksi obat)

  • SimvastatinstatinModerat

    Digoxin: During ZOCOR initiation, monitor digoxin levels. (label Simvastatin, Interaksi obat)

  • SiprofloksasinfluorokuinolonModerat

    …syndrome, uncorrected electrolyte imbalance, such as hypokalemia or hypomagnesemia and cardiac disease, such as heart failure, myocardial infarction, or bradycardia), and patients receiving Class IA antiarrhythmic agents (quinidine, procainamide), or Class III antiarrhythmic agents (amiodarone, sotalol), tricyclic antidepressants, macrolides, and antipsychotics. (label Siprofloksasin, Peringatan dan perhatian)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (label Digoksin, Interaksi obat)

  • SitalopramSSRIModerat

    Such drugs include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). (label Sitalopram, Peringatan dan perhatian)

  • SitarabinantimetabolitModerat

    Drug Interactions Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine. (label Sitarabin, Interaksi obat)

  • Solriamfetolstimulan SSPModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • SorafenibModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Sotalolpenyekat betaModerat

    Sotalol Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for proarrhythmia, in patients receiving digoxin. (label Digoksin, Interaksi obat)

  • Spironolaktonantagonis aldosteronModerat

    …Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam,… (label Digoksin, Interaksi obat)

  • SukralfatModerat

    Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. (label Sukralfat, Interaksi obat)

  • Suksinilkolinpenyekat neuromuskularModerat

    Hyperkalemia QUELICIN may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia in patients with electrolyte abnormalities and those who may have digitalis toxicity. (label Suksinilkolin, Peringatan dan perhatian)

  • …15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen,… (label Digoksin, Interaksi obat)

  • SulfasalazinsulfonamidaModerat

    Drug Interactions: Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. (label Sulfasalazin, Interaksi obat)

  • Digoxin: Concomitant use with sumatriptan and naproxen sodium tablets can increase serum concentration and prolong half-life of digoxin. (label Sumatriptan dan naproksen, Interaksi obat)

  • SunitinibModerat

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (label Sunitinib, Peringatan dan perhatian)

  • Suvoreksantsedatif-hipnotikModerat

    Digoxin: Monitor digoxin concentrations ( 7.3 ). (label Suvoreksant, Interaksi obat)

  • TakrolimusimunosupresanModerat

    …electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (label Takrolimus, Peringatan dan perhatian)

  • Tamsulosinpenyekat alfaModerat

    Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (label Tamsulosin, Interaksi obat)

  • Telmisartanpenghambat reseptor angiotensin II (ARB)Moderat

    …20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine,… (label Digoksin, Interaksi obat)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    …20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine,… (label Digoksin, Interaksi obat)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    …20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine,… (label Digoksin, Interaksi obat)

  • Terbutalinagonis beta-adrenergikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Teriparatidhormon tiroidModerat

    Parathyroid Hormone Analog Teriparatide Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity. (label Digoksin, Interaksi obat)

  • Tetrabenazinpenghambat VMAT2Moderat

    …are known to prolong QTc, including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval [see Drug Interactions ( 7.5 )]. (label Tetrabenazin, Peringatan dan perhatian)

  • Tiamazolobat antitiroidModerat

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (label Digoksin, Peringatan dan perhatian)

  • TikagrelorantiplateletModerat

    …Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate,… (label Digoksin, Interaksi obat)

  • Timololpenyekat betaModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • TolvaptanModerat

    …Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol,… (label Digoksin, Interaksi obat)

  • Torasemiddiuretik loopModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Toremifenmodulator reseptor estrogen selektifModerat

    Agents generally accepted to prolong QT interval include Class 1A (e.g., quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin,… (label Toremifen, Interaksi obat)

  • TramadolopioidModerat

    Digoxin Clinical Impact: Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity. (label Tramadol, Interaksi obat)

  • Digoxin Clinical Impact: Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity. (label Tramadol dan parasetamol, Interaksi obat)

  • TrazodonantidepresanModerat

    Digoxin or Phenytoin: Monitor for increased digoxin or phenytoin serum levels ( 7 ). (label Trazodon, Interaksi obat)

  • TriamsinolonkortikosteroidModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • TrimetoprimantibiotikModerat

    …15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen,… (label Digoksin, Interaksi obat)

  • Umeklidinium dan vilanterolantikolinergikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • Valbenazinpenghambat VMAT2Moderat

    Digoxin Clinical Implication: Concomitant use of INGREZZA or INGREZZA SPRINKLE with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp) [see Clinical Pharmacology ( 12.3 )] . (label Valbenazin, Interaksi obat)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

  • Verapamilpenghambat kanal kalsiumModerat

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (label Digoksin, Interaksi obat)

  • Vibegronagonis beta-adrenergikModerat

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (label Digoksin, Interaksi obat)

  • VilazodonSSRIModerat

    Concomitant use of VIIBRYD increased digoxin concentrations [see Clinical Pharmacology ( 12.3 )] . (label Vilazodon, Interaksi obat)

Penyebutan minor (42)

  • AdenosinantiaritmiaMinor

    Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (label Adenosin, Interaksi obat)

  • Amitriptilinantidepresan trisiklikMinor

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (label Amitriptilin, Interaksi obat)

  • Amoksapinantidepresan trisiklikMinor

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (label Amoksapin, Interaksi obat)

  • AsitretinretinoidMinor

    Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide. (label Asitretin, Interaksi obat)

  • Atrakuriumpenyekat neuromuskularMinor

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (label Digoksin, Interaksi obat)

  • Buspironobat serotonergikMinor

    The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and Synthroid®. (label Buspiron, Interaksi obat)

  • Desipraminantidepresan trisiklikMinor

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). (label Desipramin, Interaksi obat)

  • Enalaprilatpenghambat ACEMinor

    Other Cardiovascular Agents Enalaprilat injection, USP has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. (label Enalaprilat, Interaksi obat)

  • FingolimodimunosupresanMinor

    Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (label Fingolimod, Interaksi obat)

  • FondaparinuksantikoagulanMinor

    In addition, fondaparinux sodium neither influenced the pharmacodynamics of warfarin sodium, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state. (label Fondaparinuks, Interaksi obat)

  • GinsengHerbal dan suplemenMinor

    Some traditional Chinese and Ayurvedic medicine substances like Chan Su, Siberian Ginseng, Asian Ginseng, Ashwagandha or Dashen, can cause similar interference. (label Digoksin, Interaksi obat)

  • HaloperidolantipsikotikMinor

    Examples include (but are not limited to): Class 1A antiarrhythmics (e.g., procainamide, quinidine, disopyramide); Class 3 antiarrhythmics (e.g., amiodarone, sotalol); and other drugs such as citalopram, erythromycin, levofloxacin, methadone, and ziprasidone. (label Haloperidol, Interaksi obat)

  • HeparinantikoagulanMinor

    Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (label Heparin, Interaksi obat)

  • HidroksizinantihistaminMinor

    These include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin);… (label Hidroksizin, Perhatian)

  • Imipraminantidepresan trisiklikMinor

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (label Imipramin, Interaksi obat)

  • IncobotulinumtoxinApenyekat neuromuskularMinor

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (label Digoksin, Interaksi obat)

  • Kaptoprilpenghambat ACEMinor

    Cardiac Glycosides In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found. (label Kaptopril, Interaksi obat)

  • LamotriginantikonvulsanMinor

    Cardiac Rhythm and Conduction Abnormalities In vitro testing showed that lamotrigine exhibits Class IB antiarrhythmic activity at therapeutically relevant concentrations [see Clinical Pharmacology ( 12.2 )] . (label Lamotrigin, Peringatan dan perhatian)

  • Lorlatinibpenginduksi CYP3A4Minor

    • PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. (label Digoksin, Interaksi obat)

  • Milrinonpenghambat PDE3Minor

    Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin,… (label Milrinon, Interaksi obat)

  • Moeksiprilpenghambat ACEMinor

    Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (label Moeksipril, Interaksi obat)

  • Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (label Natrium zirkonium siklosilikat, Interaksi obat)

  • Nortriptilinantidepresan trisiklikMinor

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (label Nortriptilin, Interaksi obat)

  • OnabotulinumtoxinApenyekat neuromuskularMinor

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (label Digoksin, Interaksi obat)

  • PentoksifilinmetilxantinMinor

    Pentoxifylline extended-release tablets have been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. (label Pentoksifilin, Interaksi obat)

  • PerfenazinantipsikotikMinor

    Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (label Perfenazin, Interaksi obat)

  • Piridostigminpenghambat kolinesteraseMinor

    Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (label Piridostigmin, Interaksi obat)

  • PrasugrelantiplateletMinor

    Effient can be administered with aspirin (75 mg to 325 mg per day), heparin, GPIIb/IIIa inhibitors, statins, digoxin, and drugs that elevate gastric pH, including proton pump inhibitors and H 2 blockers [see Clinical Pharmacology (12.3) ] . (label Prasugrel, Interaksi obat)

  • Prazosinpenyekat alfaMinor

    Drug Interactions Prazosin hydrochloride capsules have been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and… (label Prazosin, Interaksi obat)

  • Protriptilinantidepresan trisiklikMinor

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). (label Protriptilin, Perhatian)

  • Raloksifenmodulator reseptor estrogen selektifMinor

    Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (label Raloksifen, Interaksi obat)

  • RibavirinantivirusMinor

    Drug Interactions Clinical studies of interactions of Ribavirin for Inhalation Solution, USP with other drugs commonly used to treat infants with RSV infections, such as digoxin, bronchodilators, other antiviral agents, antibiotics or anti-metabolites, have not been conducted. (label Ribavirin, Interaksi obat)

  • RisperidonantipsikotikMinor

    Digoxin Oral RISPERDAL (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. (label Risperidon, Interaksi obat)

  • Rokuroniumpenyekat neuromuskularMinor

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (label Digoksin, Interaksi obat)

  • Silodosinpenyekat alfaMinor

    Digoxin The effect of co‑administration of silodosin capsules and digoxin 0.25 mg/day for 7 days was evaluated in a clinical trial in 16 healthy males, aged 18 to 45 years. (label Silodosin, Interaksi obat)

  • Sisatrakuriumpenyekat neuromuskularMinor

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (label Digoksin, Interaksi obat)

  • TerbinafinantijamurMinor

    Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (label Terbinafin, Interaksi obat)

  • Tizanidinpelemas ototMinor

    Moderate or Weak CYP1A2 Inhibitors Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. (label Tizanidin, Interaksi obat)

  • Toksin botulinum tipe Apenyekat neuromuskularMinor

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (label Digoksin, Interaksi obat)

  • Trimipraminantidepresan trisiklikMinor

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (label Trimipramin, Interaksi obat)

  • Vekuroniumpenyekat neuromuskularMinor

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (label Digoksin, Interaksi obat)

  • Zileutonpenghambat CYP1A2Minor

    Drug-drug interaction studies in healthy subjects have been conducted with zileuton immediate-release tablets and digoxin, phenytoin, sulfasalazine, and naproxen. (label Zileuton, Interaksi obat)

Tidak ada interaksi bermakna yang dilaporkan (19)

  • Doksazosinpenyekat alfaTanpa interaksi

    In vitro data in human plasma indicate that Doxazosin has no effect on protein binding of digoxin, warfarin, phenytoin, or indomethacin. (label Doksazosin, Interaksi obat)

  • Emtrisitabin, rilpivirin, dan tenofovirantiretroviralTanpa interaksi

    RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin. (label Emtrisitabin, rilpivirin, dan tenofovir, Interaksi obat)

  • Finasteridpenghambat 5-alfa reduktaseTanpa interaksi

    Compounds that have been tested in man have included antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found. (label Finasterid, Interaksi obat)

  • FluvoksaminSSRITanpa interaksi

    Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N=8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin. (label Fluvoksamin, Interaksi obat)

  • KetoprofenOAINSTanpa interaksi

    Digoxin In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin. (label Ketoprofen, Peringatan dan perhatian)

  • Kuinaprilpenghambat ACETanpa interaksi

    Quinapril hydrochloride treatment did not affect the pharmacokinetics of digoxin. (label Kuinapril, Interaksi obat)

  • Losartanpenghambat reseptor angiotensin II (ARB)Tanpa interaksi

    Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (label Losartan, Interaksi obat)

  • LovastatinstatinTanpa interaksi

    Digoxin In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations. (label Lovastatin, Interaksi obat)

  • Montelukastantagonis reseptor leukotrienTanpa interaksi

    No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology… (label Montelukast, Interaksi obat)

  • Perindoprilpenghambat ACETanpa interaksi

    Digoxin A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with perindopril erbumine, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. (label Perindopril, Interaksi obat)

  • RilpivirinantiretroviralTanpa interaksi

    Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin. (label Rilpivirin, Interaksi obat)

  • Ropinirolagonis dopaminTanpa interaksi

    Drug Interaction Studies Digoxin: Coadministration of ropinirole (2 mg 3 times daily) with digoxin (0.125 to 0.25 mg once daily) did not alter the steady-state pharmacokinetics of digoxin in 10 patients. (label Ropinirol, Interaksi obat)

  • SertralinSSRITanpa interaksi

    Additionally, no dosage adjustment is required for diazepam, lithium, atenolol, tolbutamide, digoxin, and drugs metabolized by CYP3A4, when sertraline hydrochloride capsules is administered concomitantly [see Clinical Pharmacology ( 12.3 )] . (label Sertralin, Interaksi obat)

  • Sevelamerpengikat fosfatTanpa interaksi

    Table 5: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Dosing Recommendations Ciprofloxacin Take at least 2 hours before… (label Sevelamer, Interaksi obat)

  • Tadalafilpenghambat PDE5Tanpa interaksi

    P-glycoprotein (e.g. Digoxin) — Coadministration of tadalafil (40 mg once per day) for 10 days did not have a significant effect on the steady-state pharmacokinetics of digoxin (0.25 mg/day) in healthy subjects. (label Tadalafil, Interaksi obat)

  • TiagabinantikonvulsanTanpa interaksi

    Digoxin : Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin. (label Tiagabin, Interaksi obat)

  • Trandolaprilpenghambat ACETanpa interaksi

    Other No clinically significant pharmacokinetic interaction has been found between trandolaprilat and food, cimetidine, digoxin, or furosemide. (label Trandolapril, Interaksi obat)

  • TrospiumantikolinergikTanpa interaksi

    Concomitant use with digoxin did not affect the pharmacokinetics of either drug. (label Trospium, Interaksi obat)

  • Zaleplonsedatif-hipnotikTanpa interaksi

    Drugs with a Narrow Therapeutic Index Digoxin: Zaleplon (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days). (label Zaleplon, Interaksi obat)

Periksa Digoksin terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.